Adcetris

Adult patients w/ previously untreated CD30+ stage III or IV Hodgkin lymphoma (HL) in combination w/ doxorubicin, vinblastine & dacarbazine; relapsed or refractory CD30+ HL following autologous stem cell transplant (ASCT) or at least 2 prior therapies when ASCT or multi-agent chemotherapy is not a treatment option & at increased risk of relapse or progression following ASCT; relapsed or refractory systemic anaplastic large cell lymphoma (sALCL); CD30+ cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. Adult patients w/ previously untreated sALCL or other CD30-expressing peripheral T-cell lymphoma (PTCL) including angioimmunoblastic T-cell lymphoma & PTCL not otherwise specified in combination w/ cyclophosphamide, doxorubicin & prednisone.

IV infusion over 30 min. Previously untreated HL 1.2 mg/kg on days 1 & 15 of each 28-day cycle for 6 cycles in combination w/ doxorubicin, vinblastine & dacarbazine. Previously untreated sALCL or other CD30-expressing PTCL 1.8 mg/kg every 3 wk for 6-8 cycles in combination w/ cyclophosphamide, doxorubicin, prednisone. HL, sALCL & PTCL 1.8 mg/kg every 3 wk. Patient who achieve stable disease Min: 8 cycles & up to max: 16 cycles. CTCL 1.8 mg/kg every 3 wk up to 16 cycles. Hepatic & severe renal impairment Monotherapy: 1.2 mg/kg every 3 wk. Mild hepatic impairment Combination w/ AVD: 0.9 mg/kg every 2 wk. Combination w/ CHP: 1.2 mg/kg every 3 wk.

Hypersensitivity. Combination use w/ bleomycin.

Infusion-related reactions. Not to be administered as IV push or bolus. Discontinue use if SJS, TEN occurs & progressive multifocal leukoencephalopathy or acute pancreatitis is confirmed. Delay & reduce dose or discontinue use in patients w/ new or worsening peripheral neuropathy. Patients w/ rapidly proliferating tumor & high tumor burden; elevated BMI w/ or w/o history of DM. Monitor for emergence of possible serious & opportunistic infections. Perform prompt diagnostic evaluation for new or worsening pulmonary & GI symptoms. Monitor CBC & serum glucose prior to & during treatment. Routinely monitor liver function during treatment. May cause allergic reactions due to polysorbates. Primary prophylaxis w/ G-CSF is recommended for all patients beginning w/ 1st dose. Patients on controlled Na diet. Renal & hepatic impairment. May affect fertility. Women & men of childbearing potential should use effective contraception during & 6 mth after last dose. Not to be used during pregnancy. Lactation. Childn <18 yr.

Infection, URTI; neutropenia, anemia, thrombocytopenia; peripheral sensory & motor neuropathy, dizziness; cough, dyspnea; nausea, diarrhea, vomiting, constipation, abdominal pain, rash, pruritus, alopecia; arthralgia, myalgia, back pain; fatigue, pyrexia, infusion-related reactions, chills; decreased wt. Herpes zoster, pneumonia, oral candidiasis; hyperglycaemia; increased ALT/AST. Monotherapy: Herpes simplex. Combination therapy: Febrile neutropenia; decreased appetite; insomnia; stomatitis; bone pain. Sepsis/septic shock.

Increased MMAE exposure w/ strong CYP3A4 & P-gp inhibitor eg, ketoconazole. Reduced MMAE exposure w/ strong CYP3A4 inducer eg, rifampicin.

Targeted Cancer Therapy

L01FX05 - brentuximab vedotin ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

B